<DOC>
	<DOCNO>NCT02276196</DOCNO>
	<brief_summary>Based preclinical small-sized study non-diabetic individual , incretin-based therapy , i.e . glucagon-like peptide ( GLP ) -1 receptor agonist dipeptidyl peptidase-4 inhibitor , may hold promise prevent onset progression diabetic kidney disease . However , potential renoprotective effect agent , believe effectuate `` beyond glucose control '' , sufficiently detail human diabetes . Therefore , present study aim explore mechanistic clinical effect GLP-1 receptor agonists renal physiology biomarkers patient type 2 diabetes . Forty patient insulin-treated type 2 diabetes undergo eight week intervention lixisenatide insulin glulisine order ass change outcome parameter .</brief_summary>
	<brief_title>Effect LIXIsenatide Renal System</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Patients type 2 diabetes ( HbA1c : 6.510.0 % 4886 mmol/mol ) Stable treatment basal insulin glargine ( dose ±20 % ) metformin basal insulin glargine ( dose ±20 % ) alone least 3 month Fasting plasma glucose &lt; 10 mmol/L use &gt; 50 unit basal insulin glargine Females must postmenopausal Caucasian Age : 35 75 year Body Mass Index : &gt; 25 kg/m2 Hypertension control , i.e . &lt; 140/90 mmHg , treat angiotensinconverting enzyme inhibitor angiotensinIIreceptor blocker least 3 month . Albuminuria treat angiotensinconverting enzyme inhibitor ( ACEI ) angiotensinIIreceptor blocker ( ARB ) least 3 month . Current/chronic use follow medication : thiazolidinediones , sulfonylurea derivative , GLP1 receptor agonist , dipeptidyl peptidase ( DPP ) 4 inhibitor , glucocorticoid , immune suppressant , antimicrobial agent , chemotherapeutics , antipsychotic , tricyclic antidepressant monoamine oxidase inhibitor . Subjects diuretic , exclude drug stop duration study . Chronic use nonsteroidal antiinflammatory drug allow , unless use incidental medication ( 12 tablet ) nonchronic indication ( i.e . sport injury , headache back ache ) . However , drug take within timeframe 2 week prior renaltesting Hypoglycemia unawareness base investigator judgment History severe hypoglycemia require emergency hospital treatment within 3 month prior screen Estimated GFR &lt; 60 mL/min/1.73m2 ( determine Modification Diet Renal Disease ( MDRD ) study equation ) Pregnancy Current urinary tract infection active nephritis Recent ( &lt; 6 month ) history cardiovascular disease , include : acute coronary syndrome , chronic heart failure ( New York Heart Association grade IIIV ) , stroke transient ischemic neurologic disorder Complaints compatible establish gastroparesis , neurogenic bladder and/or incomplete bladder emptying ( determine ultrasonic bladder scan ) Active liver disease 3fold elevation liver enzyme ( aspartate aminotransferase/alanine aminotransferase ) screen History actual pancreatic disease History actual malignancy ( except basal cell carcinoma ) History actual severe mental disease Substance abuse ( alcohol : define &gt; 4 units/day ) Allergy agent use study Individuals investigator site personnel , directly affiliate study , immediate ( spouse , parent , child , sibling , whether biological legally adopt ) family investigator site personnel directly affiliate study Inability understand study protocol give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>